Sjögren's syndrome and anti-Ro52 antibody levels
Part of Immune system & allergy clinical trials.
This study looks at people with primary Sjögren's syndrome who have had a blood test for a specific antibody called anti-Ro52. The goal is to understand how antibody levels relate to the disease course and help predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with primary Sjögren's syndrome using standard criteria (ACR/EULAR 2016)
- Had a blood test for anti-Ro52 antibodies as part of routine care since 2020
- Receiving follow-up care in a participating hospital department
- No other major autoimmune disease (like lupus or rheumatoid arthritis), no organ or bone marrow transplant, and no severe immune suppression from other causes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study follows people who have tested positive for Ro/SSA or La/SSB antibodies (proteins linked to certain autoimmune conditions). It also includes a control group of people without these antibodies or any rheumatologic disease. The goal is to learn more about long-term health patterns.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
Hear when a new Sjögren´s Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.